Literature DB >> 24824935

Pathological analysis of extracapsular extension of metastatic lymph node and its potential impact on nodal clinical target volume in the radiotherapy of esophageal squamous cell carcinoma.

Z W Wang, W Zhang, W Dong, B S Li, D B Mu, W Huang, J Zhang, H S Li, Z C Zhang, H Q Lin, Y Yi.   

Abstract

There is no consensus regarding the clinical target volume (CTV) margins which surround the gross tumor volume of metastatic lymph nodes (LN) in radiotherapy of esophageal squamous cell carcinoma (ESCC). This study retrospectively assessed the distance of extracapsular extension (ECE) of metastatic LN in thoracic ESCC and defined nodal CTV margins. Histological sections of metastatic LNs from 217 patients with thoracic ESCC were re-examined. The incidence and maximal distance of ECE of metastatic LNs were assessed. The relationships between ECE and clinicopathologic features were also investigated. The ECE was found in 37.3% of patients (81/217) and 23.1% of metastatic LN (159/689), and the incidences had a significant relationship with N stage and LN size. The median distance of ECE was 1.0 mm (range, 0.2-9.7 mm). The distance of ECE showed a positive correlation with LN size (Spearman's correlation coefficient = 0.419; p<0.001). The ECE distances of LN with <10 mm diameter were significantly smaller than LN with 10-30 mm diameter (p<0.001). The 95th percentiles of ECE distances for these two groups were 3 mm and 5 mm, respectively. For pathologic LN <10 mm in diameter, a 3-mm CTV margin appears to be adequate to encompass 95% of the microscopic ECE, and for LN 10-30 mm, a 5-mm CTV margin is recommended.

Entities:  

Mesh:

Year:  2014        PMID: 24824935     DOI: 10.4149/neo_2014_042

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  5 in total

1.  Clinical Significance of the Pre-therapeutic Nodal Size in Patients Undergoing Neo-Adjuvant Treatment Followed by Esophagectomy for Esophageal Squamous Cell Carcinoma.

Authors:  Shinji Mine; Masayuki Watanabe; Yu Imamura; Akihiko Okamura; Takanori Kurogochi; Takeshi Sano
Journal:  World J Surg       Date:  2017-01       Impact factor: 3.352

2.  miR-1179 promotes cell invasion through SLIT2/ROBO1 axis in esophageal squamous cell carcinoma.

Authors:  Lixin Jiang; Yongfang Wang; Yaxiong Rong; Lianhong Xu; Ying Chu; Ying Zhang; Yonghua Yao
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 3.  The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer-A Review.

Authors:  Dan Han; Baosheng Li; Qian Zhao; Hongfu Sun; Jinling Dong; Shaoyu Hao; Wei Huang
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

4.  Lymph node metastasis is not associated with survival in patients with clinical stage T4 esophageal squamous cell carcinoma undergoing definitive radiotherapy or chemoradiotherapy.

Authors:  Liqiong Zhu; Zongxing Zhao; Ao Liu; Xin Wang; Xiaotao Geng; Yu Nie; Fen Zhao; Minghuan Li
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

5.  Influence of negative lymph node in No 7 on survival of patients with middle thoracic esophageal squamous cell carcinoma.

Authors:  Jinling Zhang; Xueyuan Heng; Yi Luo; Qingxi Fu; Zhengrong Li; Fengyuan Che; Baosheng Li
Journal:  Onco Targets Ther       Date:  2016-03-30       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.